Grifols: shares up after FDA approves new immunoglobulin
(CercleFinance.com) - The Grifols share is up almost 2% on Friday, the day after the Spanish healthcare company said its treatment for primary immunodeficiencies received regulatory approval in the US.
Xembify, the group's new 20% subcutaneous immunoglobulin used to treat primary immunodeficiencies, has been approved by the US Food and Drug Administration (FDA).
"This product will strengthen Grifols' leading position in the US immunoglobulin market," said analysts at Paris-based brokerage firm Invest Securities.
Grifols is currently a leader in the production and marketing of immunoglobulins, with a market share of over 30% in the US.
The company plans to launch Xembify in the United States in the last quarter of 2019.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Xembify, the group's new 20% subcutaneous immunoglobulin used to treat primary immunodeficiencies, has been approved by the US Food and Drug Administration (FDA).
"This product will strengthen Grifols' leading position in the US immunoglobulin market," said analysts at Paris-based brokerage firm Invest Securities.
Grifols is currently a leader in the production and marketing of immunoglobulins, with a market share of over 30% in the US.
The company plans to launch Xembify in the United States in the last quarter of 2019.
Copyright (c) 2019 CercleFinance.com. All rights reserved.